home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

6th Annual Proteins Congress 2013

 
  February 04, 2013  
     
 
Oxford Global Conferences, London
25th&26th March 2013


The Event

In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 40 speakers will present a full conference programme covering the topics outlined below. These topics have been compiled as a result of a comprehensive research process undertaken with over 20 advisory board members including VPs, Directors, Senior Research Fellows and Professors from global pharmaceutical organisations and leading research institutions.

Stream Titles

Antibodies

Protein Purification, Expression & Characterisation

Biotherapeutics

Immunogenicity & Aggregation

Day 1 Stream 1 – Antibodies

  • Antibody drug conjugates
  • Alternative antibody formats
  • Novel screening techniques
  • Bispecific antibodies and combination therapies
  • Antibody discovery, generation and selection
  • Antibody engineering

Day 1 Stream 2 – Proteins Purification, Expression & Characterisation

  • Overcoming the challenges of difficult proteins
  • Different expression systems
  • Recovery and protein purification
  • Protein folding dynamics
  • Cell line and e coli engineering
  • Protein crystallisation

Day 2 Stream 1 – Biotherapeutics

  • Novel approaches in drug discovery
  • CMC biologics strategy
  • Alternative scaffolds
  • Fusion proteins
  • Half life extension
  • Albumin binding techniques

Day 2 Stream 2 – Immunogenicity & Aggregation

  • Culture specific predictions
  • Protein aggregation
  • Emerging analytical tools
  • Immunogenicity assay development
  • Regulatory considerations
  • Sub-visible particles
 
 
Organized by: Oxford Global Conferences
Invited Speakers:
  • Nataliya Afonina
    Director clinical release & stability testing, BMS
  • Laurent Audoly
    CSO and Head R&D, Pieris
  • Dan Bach Kristensen

    Takeda, Senior Pharmaceutical Scientist

  • Debra Brennan
    Senior Scientist, Boehringer-Ingelheim
  • Katharine Cain
    Senior Scientist, UCB
  • Ho Cho
    CTO, Ambrx
  • Ciaran Cronin
    Head, parallel protein production, Pfizer
  • Jérôme Célérier
    Senior Scientist, Sisene
  • Paul Darke
    Director of Physical Biochemistry, Biogen Idec
  • Gerhardus de Jong
    Ultrecht University Professor, Biomolecular Analysis
  • Michael Doyle
    Senior Principal Scientist and Group Leader, Bristol-Myers Squibb
  • James Errey
    Associate Director Protein Biochemsitry, Heptares
  • Markus Eser
    Head of Protein Chemistry, Affimed
  • William Finlay
    Director Of Protein Discovery & Optimisation Group, Pfizer
  • Patrick Garidel
    Head of Biopharmaceutical Basic Development, Boehringer Ingelheim
  • Bernd Gerhartz
    Director Head of Protein Science Group, Novartis
  • Tariq Ghayur
    Senior Research Fellow, Abbott
  • Boris Gorovits
    Director, Pfizer
  • Maria Groves
    Senior Scientist, Lead Generation, ADPE, MedImmune
  • Steffen Hartmann
    Global Head Protein Developability, Integrated Biologics Profiling, Novartis
  • Robert Hayes
    VP & Global Lead, Johnson & Johnson
  • Sandro Keller
    Professor, Molecular Biophysics Group, University of Kaiserslautern
  • Alastair Lawson
    VP Structural Biology, UCB
  • Alexey Lugovskoy
    Senior Director of Therapeutic Design, Merrimack
  • Lorenz Mayr

    Executive Director, AstraZeneca

  • Andreas Menrad
    CSO, Ablynx
  • Dario Neri
    Professor, ETH Zurich
  • Joel Richard
    VP, Ipsen
  • Andrew Sanderson
    Principal Scientist, GSK
  • David Satijn
    Associate Director Antibody Science, Genmab
  • Ralf Schumacher
    VP & Head of Large Moleculte Research, Roche
  • Manfred Schuster
    COO, Apeiron Biologics
  • Arne Skerra
    Professor TU Munchen, Founder & CEO, XL-protein
  • Stefan Stahl
    Professor, Dean, School of Biotechnology, KTH – Royal Institute of Technology
  • Albert Stewart
    Director Structural Biology, Pfizer
  • Ali Tehrani
    CEO, Zymeworks
  • John Thompson
    Managing Director, Aldevron
  • Bernhardt Trout
    Professor Of Chemical Engineering, MIT
  • Kenneth Walker
    Scientific Director, Amgen
  • Trevor Wilkinson
    Associate Director, Protein Sciences, Lead Generation, Department of Antibody Discovery and Protein Engineering, MedImmune
  • William Winston
    Head Antibody Engineering, Aveo Oncology
  • Ulrich Wuellner
    Senior Scientist, Covagen
 
Deadline for Abstracts: Filled
 
Registration: For more information and to book online: http://www.proteins-congress.com/download-agenda/
E-mail: d.meredith@oxfordglobal.co.uk
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.